Role of HLA protein three-dimensional conformation difference in unrelated hematopoietic stem cell transplantation.
- Author:
Xian ZHANG
1
;
Yan-Ling ZHANG
;
Jian-Ling WANG
;
Chun-Rong TONG
;
Peng CAI
;
Hong-Xing LIU
;
Jing-Bo WANG
;
Xing-Yu CAO
;
Yu-Ming YIN
;
Yan-Li ZHAO
;
Yue LU
;
Yuan SUN
;
Jia-Rui ZHOU
;
Yan-Qu GAO
;
Tong WU
Author Information
1. Beijing Daopei Hospital, Beijing 100049, China. zhangxian@ludaopei.org
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Alleles;
Child;
Child, Preschool;
Female;
Genotype;
Graft vs Host Disease;
HLA Antigens;
genetics;
Hematopoietic Stem Cell Transplantation;
methods;
Histocompatibility Testing;
Humans;
Male;
Protein Conformation;
Recurrence;
Software;
Tissue Donors;
Young Adult
- From:
Journal of Experimental Hematology
2011;19(2):410-415
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to investigate the value of Histocheck and HLA-Matchmaker softwares in evaluating influence of HLA protein three dimensional conformation among individuals on outcome of unrelated donor hematopoietic stem cell transplantation (URHSCT). Data of the HLA-A/B/C/DRB1/DQB1 genotypes from 62 cases of URHSCT (HLA-allele 10/10 match 30 cases, 9/10 match 32 cases) were input into Histocheck and HLA-Matchmaker softwares respectively. The relationship between the software dissimilar scores and the 1 year overall survival (OS), incidence of aGVHD of III-IV grade and relapse rate was analyzed. The results showed that (1) with increase of the Histocheck scores, incidence of aGVHD of III-IV increased from 0% to 20% (p = 0.25), while no or mild aGVHD occurred in 70% cases with the high scores. For the relapsed cases, there was no significant difference between the cases with low scores and with highest scores (relapse rate 20%) except that 9 cases had no relapse in the group with higher score (11 - 20). (2) the analysis using HLA matchmaker software showed that incidence of aGVHD of III-IV grade increased with the increase of numbers of mismatch Eplets, arranging from 0% to 30%, the incidence of moderate aGVHD reduced (p = 0.019), whereas 60% cases in highest scores group had moderate aGVHD. No relapse occurred in the group with higher scores (≥ 3) (n = 10), whereas high relapse rate appeared in the lower score group (20%, p = 0.54). It is concluded that the value of Histocheck and HLA-Mtchmaker software for analysing the outcome of URHSCT may be similar despite of different calculating methods; for the certain pair of recipient and donor, correlation of the two score systems with incidence of aGVHD and relapse rate is similar, but with less accuracy; The HLA Matchmaker software appears better than Histocheck software in terms of correlation.
